Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Irum Khan"'
Autor:
Suman Kambhampati, Iskra Pusic, James M. Foran, John G. Edwards, John Lister, Farhad Ravandi, John M. Pagel, Charalambos Andreadis, Camille N. Abboud, Swapna Panuganti, Lois Kellerman, Martin S. Tallman, Richard David Mamelok, Delong Liu, Lawrence E. Morris, Saar Gill, Alicia Wong, Jack W. Hsu, Gary J. Schiller, Pinkal Desai, Hagop M. Kantarjian, Melham M. Solh, Irum Khan, Olga Frankfurt, Rodney Van Syoc, Patrick J. Stiff, Ramkumar Mandalam, Janice M. Brown, Wendy Stock, Luke P. Akard, Celalettin Ustun, Matthew J Wieduwilt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 29
PURPOSE Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection durin
Autor:
Jan Philipp Bewersdorf, Blanca Boluda, David Martínez-Cuadrón, Maximilian Stahl, Nikolai A. Podoltsev, Raphael Itzykson, Ellen K. Ritchie, Brendan Yoo, Thomas Cluzeau, Emma Rabinovich, Amer M. Zeidan, Florence Rabian, Ulrich Germing, Rebeca Rodríguez-Veiga, Rory M. Shallis, Steven D. Gore, Isabel Cano, Selina M. Luger, Mikkael A. Sekeres, Christine M. McMahon, Amir T. Fathi, Irum Khan, Evelyn Acuña-Cruz, Vijaya Raj Bhatt, Judith Neukirchen, Sudipto Mukherjee, Mar Tormo, Etienne Lengliné, Emmanuel Raffoux, Pau Montesinos, Wei Wei, Gail J. Roboz, Jayadev Manikkam Umakanthan, Heiko Konig, Adam R. Miller, Andrew M. Brunner
Publikováno v:
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Hyperleukocytosis in acute myeloid leukemia (AML) is associated with inferior outcomes. There is limited high quality evidence to support the benefits of leukapheresis. We retrospectively collected data from patients with newly-diagnosed AML who pres
Autor:
Selina M. Luger, Ellen K. Ritchie, Steven D. Gore, David Martínez-Cuadrón, Maximilian Stahl, Pau Montesinos, Blanca Boluda, Wei Wei, Rebeca Rodríguez-Veiga, Heiko Konig, Emma Rabinovich, Rory M. Shallis, Ulrich Germing, Amir T. Fathi, Nikolai A. Podoltsev, Isabel Cano, Adam R. Miller, Raphael Itzykson, Judith Neukirchen, Evelyn Acuña-Cruz, Mikkael A. Sekeres, Jan Philipp Bewersdorf, Brendan Yoo, Christine M. McMahon, Irum Khan, Thomas Cluzeau, Sudipto Mukhereje, Mar Tormo, Florence Rabian, Gail J. Roboz, Jayadev Manikkam Umakanthan, Etienne Lengliné, Emmanuel Raffoux, Vijaya Raj Bhatt, Andrew M. Brunner, Amer M. Zeidan
Publikováno v:
Leuk Lymphoma
LEUKEMIA & LYMPHOMA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
LEUKEMIA & LYMPHOMA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Acute myeloid leukemia (AML) is frequently associated with hyperleukocytosis [white blood cell count (WBC) of >50 or >100 × 109/L at presentation] [1]. Hyperleukocytosis also predicts a higher risk...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1a99cfad3fd8033178b8ff40c56116
https://europepmc.org/articles/PMC8273667/
https://europepmc.org/articles/PMC8273667/
Autor:
Vaibhav Agrawal, Saad Arain, Gregory S. Calip, Aysenur Esen, Kirk E. Cahill, Shawn Griffin, Olatoyosi Odenike, Ardaman Shergill, Pritesh R. Patel, Heiko Konig, Wendy Stock, Sonia Christian, Karen Sweiss, John G. Quigley, Irum Khan
Publikováno v:
Am J Hematol
Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compare
Autor:
Irum Khan, Nepheli Raptis, Wendy Stock, Melissa L. Larson, Stephanie Berg, Shira Dinner, Ami Dave, Anand Patel, Jessica K. Altman, Ivy Abraham, Garth H. Rauscher, William B Pearse, Maryam Zia, Madelyn Burkart
Publikováno v:
Blood. 138:844-844
Introduction AYA cancer patients (pts) face unique healthcare disparities due to their social development stage. AYA with AML and minorities continue to suffer reduced survival (Kahn, Cancer, 2016). Our group demonstrated that structural violence, sp
Autor:
Santosh L. Saraf, Bulent Aydogan, Eileen Hacker, Matthew Koshy, David Peace, Damiano Rondelli, Irum Khan, John G. Quigley, Nadim Mahmud, Annie L. Oh, Pritesh R. Patel, Karen Sweiss, Ralph R. Weichselbaum, Howard Ozer
Publikováno v:
Leukemia & Lymphoma. 59:1666-1671
In this phase 1 study, we tested increasing doses of total marrow irradiation (TMI) in addition to standard intravenous melphalan at 200 mg/m2 (Mel200) in the conditioning regimen prior to autologous stem cell transplant (ASCT) for multiple myeloma (
Autor:
Pritesh R. Patel, Gregory S. Calip, Betul Gok Yavuz, Eshana E. Shah, Saad Arain, John G. Quigley, Irum Khan, Sarah Stettner
Publikováno v:
Blood. 136:39-40
Background Presently, acute myeloid leukemia (AML) risk stratification is estimated prior to treatment by incorporating patient and disease characteristics. However, apart from the limited use of minimal residual disease measurement, few methodologie
Autor:
Irum Khan, Nandini Kalakota, Andrei L. Gartel, Olga Frankfurt, Marianna Halasi, Nadim Mahmud, Anand Patel, Yi Hua Chen, Nathan Aardsma, Li Liu, Rachael Schultz, John D. Crispino
Publikováno v:
JCI Insight
Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy treatment. Our previous work has shown that these favorable outcomes are linked to the cytoplasmic relocalization and inactivation of F
Autor:
Ralph R. Weichselbaum, Azhar Awan, Dolores Mahmud, Santosh L. Saraf, David Peace, Irum Khan, Damiano Rondelli, John G. Quigley, Karen Sweiss, Bulent Aydogan, Matthew Koshy, Nadim Mahmud, Pritesh R. Patel, Vincenzo DeMasi, Annie Oh
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(12):2034-2041
Here we examined the addition of intensity-modulated total marrow irradiation (TMI) delivered using a linear accelerator to a myeloablative chemotherapy conditioning regimen before allogeneic hematopoietic stem cell transplantation (HSCT). In this ph
Autor:
Sujata Gaitonde, Maryam Zia, Irum Khan, Marianna Halasi, Peter H. Gann, Nadim Mahmud, Andrei L. Gartel
Publikováno v:
Leukemia. 31(1)